Revolutionary Vaccine" Against Cancer Undergoing Tests, Stimulates Disease-Fighting Protein Production
Medical scientists are placing high hopes on a currently tested "revolutionary" vaccine that can potentially treat a range of cancer types.
A group of scientists has tested this new vaccine that employs messenger RNA (mRNA) technology known to prompt the body to produce specific proteins that fight against disease. This technique has been previously used in several COVID-19 vaccines and is now being tested with cancer patients in the United Kingdom.
According to a report in 'The Telegraph' newspaper, the aforementioned technology in the new vaccine highlights certain protein markers on cancer cell tumors, making them visible to the immune system. Consequently, the patient’s immune defenses begin attacking the cancer.
The trial is being led by scientists from the Imperial College Healthcare NHS Trust and Imperial College London. The researchers have indicated that this trial is the first of its kind and it has commenced with a number of British patients at the Hammersmith Hospital in West London. Researchers mentioned that the study would evaluate the safety and efficacy of the vaccine against lung cancer, skin cancer, and other "solid tumors."
Victoria Atkins, the UK's Minister of State for Health and Social Care, described this breakthrough as something that could make a difference in "the lives of countless individuals." She added, "The vaccine has the potential to save more lives while revolutionizing the way we treat this terrible disease with more effective and less toxic treatments."
She continued, "It reaffirms our position as a powerhouse in life sciences and our commitment to research and development."
While this research is still in its early stages and may take several years before becoming available to patients around the world, scientists have emphasized that this trial "lays a crucial foundation that brings us closer to new treatments that could potentially be less toxic and more precise."
According to a report in 'The Telegraph' newspaper, the aforementioned technology in the new vaccine highlights certain protein markers on cancer cell tumors, making them visible to the immune system. Consequently, the patient’s immune defenses begin attacking the cancer.
The trial is being led by scientists from the Imperial College Healthcare NHS Trust and Imperial College London. The researchers have indicated that this trial is the first of its kind and it has commenced with a number of British patients at the Hammersmith Hospital in West London. Researchers mentioned that the study would evaluate the safety and efficacy of the vaccine against lung cancer, skin cancer, and other "solid tumors."
Victoria Atkins, the UK's Minister of State for Health and Social Care, described this breakthrough as something that could make a difference in "the lives of countless individuals." She added, "The vaccine has the potential to save more lives while revolutionizing the way we treat this terrible disease with more effective and less toxic treatments."
She continued, "It reaffirms our position as a powerhouse in life sciences and our commitment to research and development."
While this research is still in its early stages and may take several years before becoming available to patients around the world, scientists have emphasized that this trial "lays a crucial foundation that brings us closer to new treatments that could potentially be less toxic and more precise."
